PEAR
Income statement / Annual
Last year (2022), Pear Therapeutics, Inc.'s total revenue was $12.69 M,
an increase of 201.66% from the previous year.
In 2022, Pear Therapeutics, Inc.'s net income was -$23.74 M.
See Pear Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$12.69 M
|
$4.21 M
|
$9.38 M
|
$32.56 M
|
| Cost of Revenue |
$8.18 M |
$5.23 M |
$1.72 M |
$998,000.00 |
| Gross Profit |
$4.51 M |
-$1.03 M |
$7.67 M |
$31.56 M |
| Gross Profit Ratio |
0.36 |
-0.24 |
0.82 |
0.97 |
| Research and Development
Expenses |
$48.31 M
|
$37.04 M
|
$28.08 M
|
$35.70 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$79.55 M
|
$67.62 M
|
$56.23 M
|
$27.47 M
|
| Other Expenses |
$0.00 |
-$2.05 M |
-$16.82 M |
$544,000.00 |
| Operating Expenses |
$127.86 M |
$104.66 M |
$84.31 M |
$63.17 M |
| Cost And Expenses |
$136.04 M |
$109.89 M |
$86.03 M |
$64.17 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$1.42 M |
| Interest Expense |
$3.89 M |
$0.00 |
$2.56 M |
$0.00 |
| Depreciation &
Amortization |
-$46.05 M
|
-$46.74 M
|
$1.43 M
|
-$20.10 M
|
| EBITDA |
-$169.40 M
|
-$152.43 M
|
-$75.22 M
|
-$51.70 M
|
| EBITDA Ratio |
-13.34 |
-36.22 |
-8.02 |
-1.59 |
| Operating Income Ratio
|
-9.72
|
-25.12
|
-8.17
|
-0.97
|
| Total Other
Income/Expenses Net |
$47.86 M
|
$40.54 M
|
-$12.17 M
|
$22.27 M
|
| Income Before Tax |
-$75.49 M |
-$65.14 M |
-$97.02 M |
-$9.33 M |
| Income Before Tax Ratio
|
-5.95
|
-15.48
|
-10.34
|
-0.29
|
| Income Tax Expense |
-$51.75 M |
-$44.85 M |
$3.56 M |
-$21.73 M |
| Net Income |
-$23.74 M |
-$20.29 M |
-$100.58 M |
$12.39 M |
| Net Income Ratio |
-1.87 |
-4.82 |
-10.72 |
0.38 |
| EPS |
-0.17 |
-0.18 |
-0.73 |
0.0899 |
| EPS Diluted |
-0.17 |
-0.18 |
-0.73 |
0.0899 |
| Weighted Average Shares
Out |
$138.71 M
|
$113.33 M
|
$137.80 M
|
$137.80 M
|
| Weighted Average Shares
Out Diluted |
$138.71 M
|
$113.33 M
|
$137.80 M
|
$137.80 M
|
| Link |
|
|
|
|
